



EnWave Announces Successful Animal Feeding Trials with Bioseutica, plc.

Vancouver BC, February 08, 2010.

EnWave Corporation (TSX-V:ENW | FSE:E4U) ("EnWave", or the "Company") is pleased to announce the completion of successful animal feeding trials with Neova Technologies Inc. of Abbotsford, B.C., a division of Bioseutica, plc. The study used EnWave's Radiant Energy Vacuum ("REV") dehydration technology to dry encapsulated lysozyme, a natural anti-microbial enzyme, to determine whether it can be used as a replacement for antibiotics in chicken feed. The trials showed that the dried, encapsulated enzyme permitted the same level of infection resistance as is normally obtained with pharmaceutical antibiotics. Countries around the world have been looking for ways to eliminate the routine usage of antibiotics in animal feed in order to reduce the perceived risk of anti-microbial resistance ("AMR") in human and animal populations. AMR is a serious concern in the global medical field as an increasing number of harmful micro-organisms such as bacteria, yeasts and parasites are becoming immune to the most effective measure to treat them, antibiotics.

Encapsulation is a common technique by which a sensitive material is coated or embedded in a stabilizing material in order to provide protection from harsh processing or storage conditions, as is the case with pelletized chicken feed. Researchers first encapsulated samples of Bioseutica's Entegard™ by suspending the enzyme formulation in a stabilizing hydrocolloid gel, and then dehydrated the mixture in a modified version of EnWave's *nutraREV*™ food dehydration technology. The resulting powder was then incorporated into chicken feed and fed to chickens to test their response to clostridial necrotic enteritis, a common poultry disease. The encapsulated Entegard™ medication gave protection equal to the antibiotic medication that is the common industry solution to this problem in North America.

"These results show that REV can be used as an effective, high-speed method of dehydration for encapsulated enzymes, which adds another positive result to those already received from our testing on live and active organisms including certain bacteria, viruses, antibodies and non-encapsulated enzymes," said Dr. Tim Durance, EnWave's Co-CEO. "Furthermore, we already have commercial equipment available that is capable of drying this product for Bioseutica on a large scale."

Bioseutica's proprietary Entegard™ is a purified preparation of lysozyme, a natural anti-microbial enzyme extracted from chicken egg white. Several mammals, including humans, produce lysozyme in saliva, milk and tears, where it plays an important role in the immune system, protecting against infection. This makes it a safe and natural antimicrobial for both food and pharmaceutical applications, where it has been successfully used for almost thirty years.

"We are excited that EnWave's technology increases the stability and enhances the effectiveness of Entegard™ in providing a natural, efficient, and safe alternative to antibiotics in poultry," said Mr. Stefano Ferrari, President and CEO of Bioseutica. "The companies will continue testing and exploring opportunities for REV dehydration of this and other Bioseutica products."

About Bioseutica

Bioseutica is a vertically integrated international specialty pharmaceutical group. The company's Animal Health division is at the forefront of reliable scientific research leading to innovative products and proprietary technologies. Bioseutica has manufacturing capabilities for the extraction and purification of natural proteins from hen egg white used as API, animal health ingredients and food additives. Bioseutica's other leading products include Lysoshield for food protection, Lysolac, for use in cheese, and recoup 90, the first Omega-3 sports supplement. For more information about the company, visit www.neovatech.com or www.bioseutica.com.

About EnWave

Using proprietary technologies developed in conjunction with the University of British Columbia, EnWave is focused on the development of new methods of dehydrating food and biological materials using Radiant Energy Vacuum technology under its *nutraREV™*, *powderREV™*, *bioREV™* and *freezeREV™* brands. REV technology combines microwave energy transfer under vacuum to dehydrate and alter structures and drive chemical reactions, thereby creating unique product characteristics for both food products and medical applications that include fruit, vegetables, probiotics, enzymes, proteins, food cultures, vaccines and antibodies. More information about EnWave is available at www.enwave.net.

EnWave Corporation

Dr. Tim Durance
Chairman & Co-CEO

For further information:

Mr. John McNicol, President & Co-CEO, EnWave Corporation at (604)601-8524
E-mail: john.mcnicol@enwave.net

Jennifer Thompson, V.P. Corporate Development & Investor Relations at (604)603-6549
E-mail: jthompson@enwave.net

Safe Harbour for Forward-Looking Information Statements: This press release may contain forward-looking information based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. These statements are not a guarantee of future performance and involve a number of risks, uncertainties and assumptions. There is no guarantee that the Company's REV technology can or will improve processes in the target industry; even if the Company's REV technology can be used as described in this document, there is no guarantee that such use will result in orders for the Company's REV technology. All figures comparing REV technologies to freeze drying or other dehydration technologies are provided as examples of data obtained through the Company's own scientific and testing programs; each product must be tested individually to determine the benefits of using REV.

The TSX Venture Exchange has neither approved nor disapproved the information contained herein.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.